🌟 Exciting New Publication Alert! 🌟 Explore "Peptides in Cardiology: Preventing Cardiac Aging and Reversing…
European Wellness Chairman Visits its German Biopharma Plantation
On July 9th, European Wellness Biomedical Group’s (EWBG) highly-esteemed Founder and Chairman, Prof. Dato’ Sri Dr Mike Chan, paid an important visit to Sanorell Bio Pharma Manufacturing Plant–GMP Certified, owned by European Wellness Biomedical Group (EWBG) itself.
Prof. Dato’ Sri Dr Mike Chan is a visionary leader and pioneer in the fields of regenerative medicine and stem cell therapies.
With a remarkable career spanning several decades, he has made revolutionary contributions to biomedical science, particularly in the development of innovative stem cell therapies that provide new hope to patients suffering from chronic illnesses and degenerative disorders.
His constant pursuit of excellence and innovation has propelled EWBG to the forefront of the biomedical industry.
Prof. Dato’ Sri Dr Mike Chan’s work has not only transformed regenerative medicine, but has also introduced new therapy techniques that are now being used worldwide.
His accomplishments include multiple patents, articles in prestigious scientific journals, and recognition from a variety of worldwide medical organizations.
During his visit, Prof. Dr Mike Chan had high-level conversations with the Sanorell Pharma Research team members.
With more than 80 products approved and sold in Germany and the Swiss markets for more than 4 decades.
The major goal of these discussions was to identify partnership prospects that would capitalise on Sanorell Pharma‘s substantial resources and experience.
EWBG hopes to accelerate its biotechnological discoveries and further its mission to improve global health outcomes through novel therapeutics.
These conversations covered a wide range of issues, including the most recent advances in stem cell research, potential collaborative research projects, and strategies for increasing manufacturing of stem cell-based medicines.
The manufacturing plant, located in Germany, is a valuable asset in providing critical raw materials, and resources for completed therapeutics research, and development initiatives.
The wide area of the plantation is dedicated to raising high-quality, pharmaceutical-grade plants, which are critical for extracting bioactive components used in our medicines.
Sanorell Pharma holds the only Thymus API (Active Pharmaceutical Ingredients), approved by the European Pharmacopoeia.
It produces and supplies all the other manufacturers in Germany.
EWBG’s involvement in this plantation demonstrates our dedication to using the best resources available to provide cutting-edge treatments and therapies.
The relationship with Sanorell Pharma allows us to secure a consistent and dependable supply of these key resources, which is critical for sustaining the excellent quality of our biomedical goods.
Click here to follow-up on our events: https://european-wellness.eu/events/